Efficacy of Fluoxetine - a Trial in Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1500 participants.

Also called NCT02683213

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,500 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02683213
  • EudraCT 2011-006130-16
Other papers using this trial's data
  • Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial Stroke, 2021-10 DOI, PubMed 34465201
  • Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial The Lancet. Neurology, 2020-08 DOI, PubMed 32702335

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02683213. Randomized; quadruple masking; primary purpose treatment. Start 2014-10-20 (actual); primary completion 2020-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Fluoxetine - a Trial in Stroke
Acronym
EFFECTS
Condition
Stroke
Intervention (Drug)
Fluoxetine
Intervention (Drug)
Placebo
Lead sponsor
Karolinska Institutet (class: other)
Collaborator
The Swedish Research Council (class: other government)
Collaborator
Swedish Heart Lung Foundation (class: other)
Collaborator
Stroke-Riksförbundet (class: not stated)
Collaborator
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (class: not stated)
Collaborator
Hjärnfonden (The Swedish Brain foundation) (class: not stated)
Collaborator
The Swedish Medical Association (class: other)

Record details

Record id
cardio:ct-nct02683213
Content hash
2c6a89fe1984ffd0b4d178cb9a09eb1fbc504ba7aa4e9fd62f88d678dd52fac2